APEIRON Biologics AG:製品開発パイプライン動向2015

Global Markets Directが出版した調査資料(GMDHC06924CDB)
◆英語タイトル:APEIRON Biologics AG - Product Pipeline Review - 2015
◆商品コード:GMDHC06924CDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年4月15日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

APEIRON Biologics AG – Product Pipeline Review – 2015

Summary

Global Markets Direct’s, ‘APEIRON Biologics AG – Product Pipeline Review – 2015’, provides an overview of the APEIRON Biologics AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of APEIRON Biologics AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of APEIRON Biologics AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of APEIRON Biologics AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the APEIRON Biologics AG’s pipeline products

Reasons to buy

- Evaluate APEIRON Biologics AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of APEIRON Biologics AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the APEIRON Biologics AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of APEIRON Biologics AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of APEIRON Biologics AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of APEIRON Biologics AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
APEIRON Biologics AG Snapshot 5
APEIRON Biologics AG Overview 5
Key Information 5
Key Facts 5
APEIRON Biologics AG – Research and Development Overview 6
Key Therapeutic Areas 6
APEIRON Biologics AG – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Pipeline Products – Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
APEIRON Biologics AG – Pipeline Products Glance 12
APEIRON Biologics AG – Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
APEIRON Biologics AG – Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
APEIRON Biologics AG – Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
APEIRON Biologics AG – Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
APEIRON Biologics AG – Drug Profiles 18
APN-201 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
APN-311 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
APN-301 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
APN-401 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
APN-411 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Drugs for Cancer and Related Conditions 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
APEIRON Biologics AG – Pipeline Analysis 28
APEIRON Biologics AG – Pipeline Products by Target 28
APEIRON Biologics AG – Pipeline Products by Route of Administration 29
APEIRON Biologics AG – Pipeline Products by Molecule Type 30
APEIRON Biologics AG – Pipeline Products by Mechanism of Action 31
APEIRON Biologics AG – Recent Pipeline Updates 32
APEIRON Biologics AG – Dormant Projects 34
APEIRON Biologics AG – Locations And Subsidiaries 35
Head Office 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 36
Disclaimer 37

[List of Tables]
APEIRON Biologics AG, Key Information 5
APEIRON Biologics AG, Key Facts 5
APEIRON Biologics AG - Pipeline by Indication, 2015 7
APEIRON Biologics AG - Pipeline by Stage of Development, 2015 8
APEIRON Biologics AG - Monotherapy Products in Pipeline, 2015 9
APEIRON Biologics AG - Out-Licensed Products in Pipeline, 2015 10
APEIRON Biologics AG - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
APEIRON Biologics AG - Phase III, 2015 12
APEIRON Biologics AG - Phase II, 2015 13
APEIRON Biologics AG - Phase I, 2015 14
APEIRON Biologics AG - Preclinical, 2015 15
APEIRON Biologics AG - Discovery, 2015 16
APEIRON Biologics AG - Unknown, 2015 17
APEIRON Biologics AG - Pipeline by Target, 2015 28
APEIRON Biologics AG - Pipeline by Route of Administration, 2015 29
APEIRON Biologics AG - Pipeline by Molecule Type, 2015 30
APEIRON Biologics AG - Pipeline Products by Mechanism of Action, 2015 31
APEIRON Biologics AG - Recent Pipeline Updates, 2015 32
APEIRON Biologics AG - Dormant Developmental Projects,2015 34

[List of Figures]
APEIRON Biologics AG - Pipeline by Top 10 Indication, 2015 7
APEIRON Biologics AG - Pipeline by Stage of Development, 2015 8
APEIRON Biologics AG - Monotherapy Products in Pipeline, 2015 9
APEIRON Biologics AG - Pipeline by Top 10 Target, 2015 28
APEIRON Biologics AG - Pipeline by Top 10 Route of Administration, 2015 29
APEIRON Biologics AG - Pipeline by Top 10 Molecule Type, 2015 30
APEIRON Biologics AG - Pipeline Products by Top 10 Mechanism of Action, 2015 31

【レポートのキーワード】

APEIRON Biologics AG、製品開発、製薬、医薬品、治験、研究開発、パイプライン

★調査レポート[APEIRON Biologics AG:製品開発パイプライン動向2015] (コード:GMDHC06924CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[APEIRON Biologics AG:製品開発パイプライン動向2015]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆